Efficacy and Safety of Bimekizumab in the Treatment of Psoriasis

A recent systematic review and meta-analysis encompassing randomized clinical trials sought to evaluate the efficacy and safety of bimekizumab as a potential solution for psoriasis management.

The study conducted an exhaustive search of various databases, including PubMed, Web of Science, Cochrane Library, and Embase, up to November 20, 2022, to identify randomized controlled trials reporting on bimekizumab. The trials were meticulously screened based on predefined criteria, and a meta-analysis was executed using Stata software (version 17.0) to investigate the treatment's effectiveness and safety.

A total of 6 studies, involving 1252 participants, were considered in this comprehensive analysis. When compared to the control group receiving a placebo, the bimekizumab group exhibited substantial improvements in Psoriasis Area and Severity Index (PASI) scores, specifically PASI75, PASI90, and PASI100. The relative risk (RR) for PASI75 was 20.54; for PASI90, 16.99; and for PASI100, 14.57, all favoring the bimekizumab group. Furthermore, the bimekizumab group demonstrated remarkable progress in the Investigator Global Assessment response with an RR of 22.57.

The analysis did not indicate any significant differences between the bimekizumab and placebo groups concerning treatment-emergent adverse events (TEAEs) and serious TEAEs, indicating a favorable safety profile for bimekizumab.

The study authors concluded, “Bimekizumab shows promising efficacy for the treatment of psoriasis with favorable safety records.”

Reference
Qiu Y, Zhu Y, Liu Y, Liu Q. Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials. J Dermatolog Treat. 2023;34(1):2199106. doi:10.1080/09546634.2023.2199106